재조합 단백질, 이를 코딩하는 재조합 유전자, 재조합 벡터, 및 이를 포함하는 약학조성물
    3.
    发明公开
    재조합 단백질, 이를 코딩하는 재조합 유전자, 재조합 벡터, 및 이를 포함하는 약학조성물 无效
    重组蛋白,重组基因编码它们,重组载体,包含它们的药物组合物和治疗或预防阿尔茨海默病的方法

    公开(公告)号:KR1020140127692A

    公开(公告)日:2014-11-04

    申请号:KR1020130046366

    申请日:2013-04-25

    Abstract: 본 발명은 막관통영역이 제거된 재조합된 용해성 네프릴라이신, 이의 제조방법 및 이를 포함하는 약학 조성물에 관한 것이다.

    Abstract translation: 本发明涉及:从其中除去跨膜结构域的重组可溶性中性蛋白酶; 其制造方法; 以及含有该组合物的药物组合物。 根据本发明,将去除了跨膜结构域的重组蛋白质注射到患有阿尔茨海默病的患者中,并且对减少在患者脑部积累的淀粉样蛋白β的影响。 因此,重组蛋白质可以改善患者的记忆和认知。 特别地,根据本发明,可以容易地应用重组蛋白质。 重组蛋白是位点特异性的,因此可以应用于需要治疗的局部区域。

    미코페놀레이트와 사이클로스포린을 동시에 함유한 복합정제
    4.
    发明公开
    미코페놀레이트와 사이클로스포린을 동시에 함유한 복합정제 无效
    MYCOPHENOLATE -CYCLOSPORINE组合片

    公开(公告)号:KR1020110091278A

    公开(公告)日:2011-08-11

    申请号:KR1020100011036

    申请日:2010-02-05

    Inventor: 박종상 진근우

    Abstract: PURPOSE: An immunosuppression containing mycophenolate or derivative thereof and cyclosporine is provided to sample administration effect with a case of administering mycophenolate tablets and cyclosporine tablets. CONSTITUTION: A composite tablet contains cyclosporine and mycophenolate. The cyclosporine is cyclosporine A. The mycophenolate is mycophenolate or derivative thereof. An immunosuppressant contains 3-9 weight ratio of cyclosporine A, 29-87 weight ratio of mycophenolate mofetil, 10-30 weight ratio of hydroxypropyl methyl cellulose, 5-25 weight ratio of avicel PH101, and 1 weight ratio of stearate magnesium salt. The mycophenolate mofetil is denoted by (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate. The hydroxypropyl methyl ceullose is a water swellable polymer.

    Abstract translation: 目的:提供含有霉酚酸酯或其衍生物和环孢菌素的免疫抑制剂,用于施用霉酚酸片剂和环孢菌素片剂的样品施用效果。 构成:复合片含有环孢菌素和霉酚酸酯。 环孢菌素是环孢霉素A.霉酚酸酯是霉酚酸酯或其衍生物。 免疫抑制剂含有3-9重量比的环孢菌素A,29-87重量比的霉酚酸酯,10-30重量比的羟丙基甲基纤维素,5-25重量比的avicel PH101,和1重量比的硬脂酸镁盐。 霉酚酸酯由(E)-6-(1,3-二氢-4-羟基-6-甲氧基-7-甲基-3-氧代-5-异苯并呋喃基)-4-甲基-4-己烯酸酯表示。 羟丙基甲基纤维素是水溶胀性聚合物。

    미코페놀레이트 모페틸을 함유한 서방성 면역 억제제
    5.
    发明公开
    미코페놀레이트 모페틸을 함유한 서방성 면역 억제제 无效
    含有MYCOPHENOLATE MOFETIL的免疫抑制剂的持续释放剂

    公开(公告)号:KR1020110091252A

    公开(公告)日:2011-08-11

    申请号:KR1020100010994

    申请日:2010-02-05

    Inventor: 박종상 주재량

    Abstract: PURPOSE: A sustained release immunosuppressant containing mycophenolate mofetil is provided to remarkably maintain the action without side effect to gastrointestine. CONSTITUTION: An immunosuppressant contains 50-80 weight ratio of Mycophenolate mofetil, 0-30 weight ratio of hydroxypropylmethyl cellulose, 3-30 weight ratio of avicel PH-101, 0-10 weight ratio of povidone, and 1 weight ratio of stearate magnesium salt. A formulation of the immunosuppressant additionally contains antiseptic, solubilizer, stabilizing agent, wetting agent, emulsifier, coloring agent, flavoring agent, buffer, coating agent, and/or antioxidant.

    Abstract translation: 目的:提供含有霉酚酸酯的持续释放免疫抑制剂,以显着维持对胃肠道无副作用的作用。 构成:免疫抑制剂含有50-80重量比的霉酚酸酯,0-30重量比的羟丙基甲基纤维素,3-30重量比的avicel PH-101,0-10重量比的聚维酮和1重量比的硬脂酸镁盐 。 免疫抑制剂的配方还含有防腐剂,增溶剂,稳定剂,润湿剂,乳化剂,着色剂,调味剂,缓冲剂,包衣剂和/或抗氧化剂。

    의료용 품물의 약물 코팅 방법
    6.
    发明公开
    의료용 품물의 약물 코팅 방법 无效
    医疗用药物涂层方法

    公开(公告)号:KR1020110085700A

    公开(公告)日:2011-07-27

    申请号:KR1020100005618

    申请日:2010-01-21

    CPC classification number: A61L33/04 A61B17/06166 A61L17/145 A61L33/08

    Abstract: PURPOSE: A method for coating medical things with medicine is provided to easily apply medicine on medical things like silk material and polypropylene. CONSTITUTION: A method for coating medical things with medicine comprises: a mixing step of making a compound material that is mixed with gel and medicine in order to coat the surface of medical things; and a compound material coating step of coating the surface of the medical things with the compound material. The medicine mixed with compound material is water soluble medicine. The gel is mixed with gelatin, dextran, and glyceraldehyde.

    Abstract translation: 目的:提供用药物涂药物的方法,可以很容易地将药物应用于丝绸材料和聚丙烯等医疗用品上。 构成:用药物涂敷医药物的方法包括:混合步骤,制备与凝胶和药物混合的复合材料,以涂覆医用物品的表面; 以及复合材料涂覆步骤,用复合材料涂覆医用物品的表面。 与复方材料混合的药物是水溶性药物。 凝胶与明胶,葡聚糖和甘油醛混合。

Patent Agency Ranking